Quarterly report pursuant to Section 13 or 15(d)

License Revenue (Details)

v3.21.2
License Revenue (Details) - USD ($)
$ in Thousands
1 Months Ended 3 Months Ended 9 Months Ended
Aug. 31, 2020
Jul. 31, 2018
Jun. 30, 2018
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Licensing Arrangements              
Total revenue       $ 181 $ 3,000 $ 568 $ 3,000
Pharmbio Korea Inc | Licensing agreements              
Licensing Arrangements              
Upfront payment     $ 3,000        
Commercialization milestone payments     500        
Withholding taxes     $ 500        
Time period for written notice to terminate license agreement     180 days        
Pharmbio Korea Inc | Licensing agreements | Minimum              
Licensing Arrangements              
Time period to form a committee prior to the anticipated date of regulatory approval     6 months        
Pharmbio Korea Inc | Licensing agreements | Maximum              
Licensing Arrangements              
Royalties on product sales, percentage     20.00%        
Jiangsu Nhwa Pharmaceutical Co Ltd | Licensing agreements              
Licensing Arrangements              
Upfront payment   $ 2,500          
Commercialization milestone payments $ 3,000            
Withholding taxes 300 $ 300          
Milestone payment upon regulatory approval 3,000            
Milestone payment upon sales targets reached in China $ 6,000            
Royalty percentage on net product sales in China after milestones met 10.00%            
Jiangsu Nhwa Pharmaceutical Co Ltd | Licensing agreements | Minimum              
Licensing Arrangements              
Time period to form a committee prior to the anticipated date of regulatory approval 6 months            
Jiangsu Nhwa Pharmaceutical Co Ltd | Licensing agreements | Maximum              
Licensing Arrangements              
Time period for written notice to terminate license agreement 180 days            
License revenue              
Licensing Arrangements              
Total revenue       $ 69 $ 3,000 $ 69 $ 3,000